OBJECTIVE: This study was initiated to investigate the effects of Roux-en-Y gastric bypass (RYGB) surgery on hepatic glucose metabolism and hepatic expression of protein tyrosine phosphatase 1B (PTP1B) in obese rats. METHODS: Body weight, glucose, intraperitoneal glucose, insulin, and pyruvate tolerance tests were performed pre- and postoperatively, and plasma lipid, insulin and glucagon-like peptide 1 (GLP-1) were measured. The mRNA levels of G6Pase, Pepck, Gsk-3β and Gys-2, and the expression levels of PTP1B mRNA, protein, and other components of the insulin signaling pathway were measured by using RT-PCR and western blotting. The intracellular localization of PTP1B and hepatic glycogen deposition was also observed. RESULTS: RYGB surgery-treated rats showed persistent weight loss, significantly improved glucose tolerance, pyruvate tolerance, and dyslipidemia, as well as increased insulin sensitivity, hepatic glycogen deposition and increased plasma GLP-1 in obese rats. RT-PCR analyses showed Pepck, G6Pase, and Gsk-3β mRNA to be significantly decreased, and Gys-2 mRNA to be significantly increased in liver tissue in the RYGB group (p < 0.05 vs. high-fat diet (HFD) or HFD + sham group); in addition, the expression of PTP1B were significantly decreased and insulin signaling were improved in the RYGB group (p < 0.05 vs. HFD or HFD + sham group). CONCLUSION: RYGB can improve hepatic glucose metabolism and down-regulate PTP1B in obese rats. An increased circulating GLP-1 concentration may be correlated with the effects following RYGB in obese rats.
OBJECTIVE: This study was initiated to investigate the effects of Roux-en-Y gastric bypass (RYGB) surgery on hepatic glucose metabolism and hepatic expression of protein tyrosine phosphatase 1B (PTP1B) in obeserats. METHODS: Body weight, glucose, intraperitoneal glucose, insulin, and pyruvate tolerance tests were performed pre- and postoperatively, and plasma lipid, insulin and glucagon-like peptide 1 (GLP-1) were measured. The mRNA levels of G6Pase, Pepck, Gsk-3β and Gys-2, and the expression levels of PTP1B mRNA, protein, and other components of the insulin signaling pathway were measured by using RT-PCR and western blotting. The intracellular localization of PTP1B and hepatic glycogen deposition was also observed. RESULTS: RYGB surgery-treated rats showed persistent weight loss, significantly improved glucose tolerance, pyruvate tolerance, and dyslipidemia, as well as increased insulin sensitivity, hepatic glycogen deposition and increased plasma GLP-1 in obeserats. RT-PCR analyses showed Pepck, G6Pase, and Gsk-3β mRNA to be significantly decreased, and Gys-2 mRNA to be significantly increased in liver tissue in the RYGB group (p < 0.05 vs. high-fat diet (HFD) or HFD + sham group); in addition, the expression of PTP1B were significantly decreased and insulin signaling were improved in the RYGB group (p < 0.05 vs. HFD or HFD + sham group). CONCLUSION: RYGB can improve hepatic glucose metabolism and down-regulate PTP1B in obeserats. An increased circulating GLP-1 concentration may be correlated with the effects following RYGB in obeserats.
Authors: Lale Ozcan; Xiaoming Xu; Shi-Xian Deng; Devram S Ghorpade; Tiffany Thomas; Serge Cremers; Brian Hubbard; Michael H Serrano-Wu; Matthias Gaestel; Donald W Landry; Ira Tabas Journal: Diabetes Date: 2015-06-11 Impact factor: 9.461
Authors: Janice M Zabolotny; Kendra K Bence-Hanulec; Alain Stricker-Krongrad; Fawaz Haj; Yongping Wang; Yasuhiko Minokoshi; Young-Bum Kim; Joel K Elmquist; Louis A Tartaglia; Barbara B Kahn; Benjamin G Neel Journal: Dev Cell Date: 2002-04 Impact factor: 12.270
Authors: Francesco Rubino; Michel Gagner; Paolo Gentileschi; Subhash Kini; Shoji Fukuyama; John Feng; Ed Diamond Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: Glenn S Gerhard; Amanda M Styer; G Craig Wood; Stephen L Roesch; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Christopher D Still; George Argyropoulos Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Charles Robb Flynn; Vance L Albaugh; Steven Cai; Joyce Cheung-Flynn; Phillip E Williams; Robert M Brucker; Seth R Bordenstein; Yan Guo; David H Wasserman; Naji N Abumrad Journal: Nat Commun Date: 2015-07-21 Impact factor: 14.919
Authors: Kirk M Habegger; Kristy M Heppner; Sarah E Amburgy; Nickki Ottaway; Jenna Holland; Christine Raver; Erin Bartley; Timo D Müller; Paul T Pfluger; Jose Berger; Mouhamadoul Toure; Stephen C Benoit; Richard D Dimarchi; Diego Perez-Tilve; David A D'Alessio; Randy J Seeley; Matthias H Tschöp Journal: Diabetes Date: 2013-11-01 Impact factor: 9.461
Authors: María Belén Acevedo; Ramiro Ferrando; Bruce W Patterson; J Christopher Eagon; Samuel Klein; Marta Yanina Pepino Journal: Surg Obes Relat Dis Date: 2018-11-02 Impact factor: 4.734
Authors: Ankita Srivastava; Matthew Stevenson; Jenny Lee; Christopher Hall; Thomas Palaia; Chaohui Lisa Zhao; Raymond Lau; Collin Brathwaite; Louis Ragolia Journal: Obes Surg Date: 2022-04-14 Impact factor: 3.479